Five-Year Agreement Expands on Prior Supply
Agreement
Fluidigm Corporation (NASDAQ:FLDM) and OpGen, Inc. (NASDAQ:OPGN)
today announced an expanded relationship and new agreement that
includes collaborating on the development of test kits and custom
analytic instruments for identification, screening, and
surveillance testing of multi-drug resistance organism (MDRO) genes
of pathogens, such as bacteria, fungi and viruses.
The agreement establishes a framework for Fluidigm and OpGen to
develop MDRO tests utilizing Fluidigm components and instruments,
initially based on Fluidigm’s Juno™ instrument for automating SNP
genotyping assays and Fluidigm’s Biomark™ system for endpoint and
real-time PCR detection. Fluidigm and OpGen plan to cooperate on
quality, regulatory, and compliance as needed. The initial term of
the agreement is for five years with the potential to extend for an
additional five-year term.
OpGen President Kevin Krenitsky, MD, said, “We are excited to
expand our strategic collaboration with Fluidigm. We anticipate
working together to develop improved solutions and workflows for
testing multi-drug resistant organisms and other pathogens. Our
Acuitas® MDRO Gene Test and Resistome Test both utilize Fluidigm
microfluidic technologies. With this expanded relationship, OpGen
anticipates developing customized solutions for our CLIA lab
customers, strategic partners and testing laboratories
globally.”
“The rise of multi-drug resistant organisms is a major health
issue globally. In addition to OpGen’s pioneering work in this
field, our two companies intend to work together to address these
needs and to seek government funding for development of new
products based on Fluidigm’s microfluidic technologies and OpGen’s
molecular testing services and products, including molecular
information analytics,” said Steve McPhail, Fluidigm General
Manager, Production Genomics.
About MDROs
Multi-drug resistant organisms (MDROs) are mainly common
bacteria that have developed resistance to multiple classes of
antibiotics. They are a leading cause of hospital-acquired
infections and are associated with an increase in morbidity and
mortality. Each year, more than two million Americans acquire
infections that are resistant to antibiotics. Asymptomatic carriers
are at a higher risk of an MDRO infection and become reservoirs for
transmission to other patients in health care systems if not
accurately identified early. Since there are many types of
antibiotic resistant organisms, and the way they cause disease is
dictated by their genetics, knowing the exact genetic profile of
these organisms is a key step to preventing their ability to
infect.
Use of Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to OpGen’s product development
plans, and objectives, expectations and/or strategies relating to
such product development efforts. Forward-looking statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from currently anticipated results,
including challenges inherent in developing, manufacturing,
launching, marketing, and selling new products; and OpGen’s sales,
marketing, manufacturing, and distribution capabilities.
Information on these and additional risks affecting OpGen’s
business and operating results are contained in its filings with
the Securities and Exchange Commission, including its Quarterly
Report on Form 10-Q for the quarter ended March 31, 2015, and other
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof and
OpGen disclaims any obligation to update these statements except as
may be required by law.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to Fluidigm’s product and
marketing plans, objectives, expectations and/or strategies.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results, including the potential impact
on the collaboration announced today of risks relating to
Fluidigm’s previously disclosed intent to register with the United
States Food & Drug Administration (FDA) as a medical device
manufacturer and to seek certain clearances and approvals from the
FDA and other regulatory authorities; challenges inherent in
developing, manufacturing, launching, marketing, and selling new
products; Fluidigm’s sales, marketing, manufacturing, and
distribution capabilities; and interruptions or delays in the
supply of components or materials for, or manufacturing of, its
products. Information on these and additional risks affecting
Fluidigm’s business and operating results are contained in its
filings with the Securities and Exchange Commission, including its
Quarterly Report on Form 10-Q for the quarter ended March 31, 2015,
and other filings with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof
and Fluidigm disclaims any obligation to update these statements
except as may be required by law.
About OpGen
OpGen, Inc. is an early commercial-stage company using molecular
testing and bioinformatics to assist healthcare providers in
combating multi-drug resistant bacterial infections. The company's
products and services are being developed to enable the rapid
identification of hospital patients who are colonized or infected
with life-threatening, multi-drug resistant organisms, or MDROs.
The company's products include the Acuitas MDRO Gene Test, the
Acuitas Resistome and Whole Genome Sequencing Tests and the Acuitas
Lighthouse MDRO Management System. In addition, the company has
more than 10 years of experience mapping microbial, plant and human
genomes. Learn more at www.opgen.com.
Acuitas® and OpGen® are trademarks of OpGen, Inc.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life
science analytical and preparatory systems for growth markets such
as single-cell biology and production genomics. We sell to leading
academic institutions, clinical laboratories, and pharmaceutical,
biotechnology, and agricultural biotechnology companies worldwide.
Our systems are based on proprietary microfluidics and
multi-parameter mass cytometry technology, and are designed to
significantly simplify experimental workflow, increase throughput,
and reduce costs, while providing excellent data quality. Fluidigm
products are provided for Research Use Only. Not for use in
diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account
(@Fluidigm), Facebook page (https://www.facebook.com/Fluidigm), and
LinkedIn page
(https://www.linkedin.com/company/fluidigm-corporation) as channels
of distribution of information about our products, our planned
financial and other announcements, our attendance at upcoming
investor and industry conferences, and other matters. Such
information may be deemed material information and we may use these
channels to comply with our disclosure obligations under Regulation
FD. Therefore, investors should monitor our website and our social
media accounts in addition to following our press releases, SEC
filings, public conference calls, and webcasts.
For more information, please visit: www.fluidigm.com
Fluidigm, the Fluidigm logo, BioMark, and Juno are trademarks or
registered trademarks of Fluidigm Corporation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150713005804/en/
OpGenMichael Farmer, 240-813-1284Director,
Marketingmfarmer@opgen.comInvestorRelations@opgen.comorInvestorsLHAKim
Sutton Golodetz, 212-838-3777kgolodetz@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.comorMediaLisa Guiterman,
301-217-9353lisa.guiterman@gmail.comorFluidigmHoward
High650-266-6081 (office)510-786-7378 (mobile)Fellow, Corporate
Communication and Press RelationsFluidigm
Corporationhoward.high@fluidigm.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024